Navigation Links
CASI Pharmaceuticals Reports Second Quarter 2014 Financial Results
Date:8/14/2014

res as we advance the development of ENMD-2076." 

Commenting on the Company's most recent milestones, Dr. Ren added, "Subsequent to the close of the second quarter the Company was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for ENMD-2076 in hepatocellular carcinoma and was also granted approval from China's Food and Drug Administration (CFDA) to start a Phase II trial of ENMD-2076 in Chinese patients with triple-negative breast cancer (TNBC).  CFDA's approval will allow CASI to fully embrace our U.S./China business strategy and we look forward to starting a TNBC trial in China.  The data from these patients will also be used in support of our U.S. regulatory strategy." 

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma.  CASI is completing a Phase II trial of ENMD-2076 in ovarian cancer.  In addition, CASI is conducting a dual-institutional Phase II study of ENMD-2076 in triple-negative breast cancer, a Phase II study in advanced/metastatic soft tissue sarcoma and a Phase II ovarian clear cell carcinomas. ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia, and
'/>"/>

SOURCE CASI Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
2. Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
3. Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
4. Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino
5. Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
6. AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results
7. Inovio Pharmaceuticals Reports 2014 Second Quarter Financial Results
8. Absorption Pharmaceuticals CEO Jeff Abraham Discusses Promescent on KFI
9. Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.
10. Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes
11. AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... California , September 1, 2015 ... is segmented on the basis of sectors, products ... chronic diseases globally coupled with the increasing demand ... diseases are expected to propel the growth for ... manage biological information efficiently is known as bioinformatics. ...
(Date:9/1/2015)... Aug. 31, 2015 Research and Markets ( ... "Regulatory Affairs for Support Staff (London, UK - September ... This two day course provides an introduction to ... and has been designed specifically for those working in ... gain an overview of EU regulatory procedures required to ...
(Date:9/1/2015)... 2015 - The ... egistry data presented at ESC Congress ... the evolution of manag ing AF in ... -   The first-ever two-year outcomes from the Global Anticoagulant ... expose that all-cause death was the most frequent major event in more than ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
... U.S. Food and Drug Administration today approved Ferriprox (deferiprone) ... transfusions in patients with thalassemia, a genetic blood disorder ... prior chelation therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... iron in the body from the frequent blood transfusions ...
... SAN RAMON, Calif., Oct. 14, 2011 Armanino ... successful company-wide Microsoft Dynamics AX implementation and the ... MES (Manufacturing Engineering System) to streamline the production ... equipment.  Microsoft Dynamics AX is a comprehensive business ...
Cached Medicine Technology:FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 2FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 3Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 2Armanino Consulting Completes Integration of Microsoft Dynamics AX and Camstar MES for dpiX 3
(Date:9/1/2015)... ... 2015 , ... Stress comes in many different forms and ... can lead to very serious, life-altering events. Fortunately nature offers a range of ... manufacturer MediHerb has coupled therapeutic doses of Rhodiola and Schisandra herbs ...
(Date:9/1/2015)... ... 01, 2015 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... the LATINA Style 50 Report that recognizes companies that provide the best career opportunities ... BCBSNJ climbs from number 24 to 21 of the 50 Best Companies for Latinas. ...
(Date:9/1/2015)... ... September 01, 2015 , ... As ... Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand ... in San Francisco, Doctor On Demand provides immediate access to Board Certified physicians ...
(Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider ... vital signs and activity, today announced its integration with leading veterinary Practice Management ... widely-adopted veterinary hospital Practice Management Software packages in the US. Practice Management Software ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2
... one expert says there,s a hitch: Kids can take them ... of past research shows cheaper, removable splints are as safe ... fractures in children. , But one U.S. orthopedic expert disagrees, ... split at inappropriate times and cause further damage to themselves. ...
... showed some cancer patients with recurrent lymphoma benefited from ... the University of Alabama at Birmingham (UAB). , The ... meeting of the American Association for Cancer Research in ... AME-133v had a potent tumor-halting response in patients with ...
... Coalition to Tackle Number One Cause of Death ... Stressing the major toll that,chronic diseases take on ... of influential New Jersey residents in the health,care, ... Jersey,Partnership to Fight Chronic Disease (PFCD), a coalition ...
... As potential cancer therapies proliferate, researchers and clinicians ... accurately predict which patients will receive the most benefit. ... Annual Meeting, April 12-16, 2008, researchers present data on ... doctors can more effectively measure response to commonly used ...
... University of Chicago study shows that older people remain vital ... popular notion that they are more likely to be socially ... have fewer intimate relationships, they may respond to social loss ... spend time with their neighbors than those in their 50s. ...
... of buying care that,reflects patient centered medical ... The Patient Centered,Primary Care Collaborative (PCPCC), a ... and 330,000 primary care,physicians, today introduced a ... care that reflects the patient centered medical ...
Cached Medicine News:Health News:Splints as Good as Plaster Casts for Minor Fractures 2Health News:New Jersey Leaders Join Forces to Battle Chronic Disease 2Health News:New Jersey Leaders Join Forces to Battle Chronic Disease 3Health News:New Jersey Leaders Join Forces to Battle Chronic Disease 4Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 3Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 4Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 5Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 6Health News:Older Americans are more socially engaged than many people may think 2Health News:Older Americans are more socially engaged than many people may think 3Health News:Patient Centered Primary Care Collaborative Releases New Guidelines for Health Care Purchasers 2Health News:Patient Centered Primary Care Collaborative Releases New Guidelines for Health Care Purchasers 3Health News:Patient Centered Primary Care Collaborative Releases New Guidelines for Health Care Purchasers 4
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: